Krishna Institute of Medical Sciences Limited (KIMS) AI Stock Analysis

• Market Cap: ₹288.08B
• Dividend Yield: N/A
• Average Volume (3M): 23.04K
• Price to Earnings (P/E): 76.5
• Beta (1Y): 0.59
• Revenue Growth: 24.71%
• EPS Growth: 19.17%
• Country: IN
• Employees: 5,013
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 2.00
• Shares Outstanding: 400,138,950
• 10 Day Avg. Volume: 26,167
• 30 Day Avg. Volume: 23,042
• PEG Ratio: 2.68
• Price to Book (P/B): 11.57
• Price to Sales (P/S): 8.15
• P/FCF Ratio: -57.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹745.50
• Price Target Upside: 1.53% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 65 Neutral
• Price Target: ₹766.00 ▲(4.32% Upside)

Krishna Institute of Medical Sciences Limited demonstrates strong financial performance with significant revenue and profit growth. However, the stock's high valuation and bearish technical indicators suggest caution. The company's increased leverage and negative free cash flow are potential risks that need monitoring.

Krishna Institute of Medical Sciences Limited Business Overview & Revenue Model

Company Description

Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand name in India. The company offers range of specialties, including cardiac, dental, neuro, oncological, orthopedic, renal, reproductive, and robotic sciences, as well as gastroenterology and hepatology, heart and lung transplant, organ transplantation, mother and childcare, and pediatrics services. It also focuses on accident, biochemistry, anesthesiology, bariatric surgery, andrology and infertility, arthroscopy, alzheimers, bone, joint center specialties, and others. The company was incorporated in 1973 and is based in Secunderabad, India.

How the Company Makes Money

KIMS generates revenue primarily through patient care services, including inpatient and outpatient treatments, surgeries, and diagnostic services. The company earns money by charging patients for hospital stays, medical procedures, consultations, and specialized treatments. Additional revenue streams include partnerships with insurance companies for cashless treatment options, government health schemes, and corporate tie-ups for employee health programs. KIMS may also benefit from ancillary services such as pharmacy sales, laboratory services, and health check-up packages, which contribute to its overall earnings.

Krishna Institute of Medical Sciences Limited Financial Statement Overview

Summary

Krishna Institute of Medical Sciences Limited shows strong financial health with robust revenue and profit growth, supported by stable margins. Despite increased leverage, the company maintains a solid equity base and strong operational cash generation, although high capital expenditures have led to negative free cash flow.

Income Statement

Krishna Institute of Medical Sciences Limited has demonstrated a robust revenue growth trajectory, increasing from 16.5 billion in 2022 to 30.4 billion in 2025, indicating strong market demand and operational efficiency. The gross profit margin remained stable around 62-63%, showcasing effective cost management. Notably, the net profit margin improved to 12.7% in 2025 from 12.4% in 2024, suggesting enhanced profitability. The EBIT margin also showed a strong increase to 62.9% in 2025, reflecting operational excellence. Overall, the company exhibits impressive growth and profitability.

Balance Sheet

The balance sheet of Krishna Institute of Medical Sciences Limited reflects a solid equity base with stockholders' equity increasing to 21.4 billion in 2025. The debt-to-equity ratio rose to 1.20 in 2025, indicating increased leverage which could pose a risk if not managed carefully. However, the equity ratio remains healthy at 37.3%, suggesting a stable financial foundation. Return on equity improved to 18% in 2025, signifying effective utilization of shareholder funds. While leverage has increased, the company maintains a strong equity position.

Cash Flow

The cash flow analysis reveals that operating cash flow has been steadily increasing, reaching 5.8 billion in 2025, highlighting robust operational performance. However, free cash flow has been negative, mainly due to high capital expenditures which could limit liquidity in the short term. The operating cash flow to net income ratio of 1.51 in 2025 suggests strong earnings quality. Despite the negative free cash flow, the company shows solid cash generation from operations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	32.18B	30.35B	24.98B	21.98B	16.51B	13.30B
Gross Profit	22.12B	9.10B	14.82B	6.99B	10.34B	4.19B
EBITDA	8.24B	7.83B	6.53B	6.51B	5.42B	3.78B
Net Income	3.77B	3.85B	3.10B	3.36B	3.33B	2.01B
Balance Sheet
Total Assets	0.00	57.36B	38.52B	29.41B	19.07B	14.36B
Cash, Cash Equivalents and Short-Term Investments	1.02B	1.02B	1.32B	1.34B	1.90B	2.84B
Total Debt	0.00	25.57B	13.55B	6.78B	2.57B	3.16B
Total Liabilities	-24.19B	33.17B	17.59B	10.03B	4.97B	5.60B
Stockholders Equity	24.19B	21.38B	18.28B	16.70B	13.87B	8.64B
Cash Flow
Free Cash Flow	0.00	-4.27B	-1.26B	-1.42B	1.54B	2.62B
Operating Cash Flow	0.00	5.82B	5.21B	4.32B	3.24B	3.56B
Investing Cash Flow	0.00	-11.16B	-7.53B	-5.47B	-4.12B	-3.54B
Financing Cash Flow	0.00	5.43B	2.17B	196.42M	609.99M	98.19M

Krishna Institute of Medical Sciences Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 734.30
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KIMS, the sentiment is Neutral. The current price of 734.3 is above the 20-day moving average (MA) of 712.25, above the 50-day MA of 731.43, and above the 200-day MA of 665.93, indicating a neutral trend. The MACD of -2.00 indicates Negative momentum. The RSI at 48.53 is Neutral, neither overbought nor oversold. The STOCH value of 51.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:KIMS.

Krishna Institute of Medical Sciences Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDANTA	―	₹372.21B	68.98	―	0.04%	15.42%	10.66%
NH	―	₹362.74B	45.97	―	0.25%	12.09%	-2.79%
HCG	―	₹103.33B	275.51	―	―	16.85%	-29.57%
KIMS	―	₹288.08B	76.52	―	―	24.71%	19.17%
FORTIS	―	₹824.98B	94.33	―	0.09%	14.04%	32.99%
ASTERDM	―	₹364.14B	110.81	―	0.71%	-53.19%	-94.01%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%